Evofem Biosciences Temettü
Temettü kriter kontrolleri 0/6
Evofem Biosciences does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-9.2%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -9.2% |
| Gelecekteki Temettü Verimi | n/a |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if EVFM's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if EVFM's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
| Evofem Biosciences Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (EVFM) | n/a |
| Pazarın Alt %25'i (US) | 1.5% |
| Pazarın En İyi %25'i (US) | 4.5% |
| Sektör Ortalaması (Pharmaceuticals) | 2.3% |
| Analist tahmini (EVFM) (3 yıla kadar) | n/a |
Önemli Temettü: Unable to evaluate EVFM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate EVFM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate EVFM's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as EVFM has not reported any payouts.